RecruitingPhase 1NCT07764146

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

An Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of VY1706 in Participants With Early Alzheimer's Disease

Sponsor

Voyager Therapeutics

Enrollment

18 participants

Start Date

Sep 3, 2026

Study Type

INTERVENTIONAL

Conditions

Alzheimer s Disease

Summary

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Eligibility

Min Age: 30 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Anti-AAV9 Total Antibody (TAb) Assay, a drug called VY1706 High Dose, and others for people with alzheimer s disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 30 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.